(https://www.cnbc.com/2026/06/17/huntingtons-disease-drugmaker-uniqure-to-seek-fda-ok-for-gene-therapy.html) after months of public tension looks like redemption theater, but the real signal is buried in the insider flows. Huntington's disease gene therapy has zero competition — this is a rare-disease moat.

Research these companies